Bitcoin halving
What does that mean?
$2.76T
Total marketcap
$108.91B
Total volume
BTC 49.71%     ETH 15.35%
Dominance

I-Mab IMAB Stock

1.86 USD {{ price }} -0.534759% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
150.1M USD
LOW - HIGH [24H]
1.84 - 1.9 USD
VOLUME [24H]
193.67K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.74 USD

I-Mab Price Chart

I-Mab IMAB Financial and Trading Overview

I-Mab stock price 1.86 USD
Previous Close 3.08 USD
Open 3.08 USD
Bid 3.09 USD x 1800
Ask 3.1 USD x 900
Day's Range 2.99 - 3.17 USD
52 Week Range 2.73 - 12.76 USD
Volume 345.34K USD
Avg. Volume 347.32K USD
Market Cap 256.99M USD
Beta (5Y Monthly) 0.97191
PE Ratio (TTM) N/A
EPS (TTM) -3.74 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 34.5 USD

IMAB Valuation Measures

Enterprise Value -3105556224 USD
Trailing P/E N/A
Forward P/E -2.095238
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) -1.159915
Price/Book (mrq) 0.08496786
Enterprise Value/Revenue 14.017
Enterprise Value/EBITDA 1.67

Trading Information

I-Mab Stock Price History

Beta (5Y Monthly) 0.97191
52-Week Change -69.95%
S&P500 52-Week Change 19.24%
52 Week High 12.76 USD
52 Week Low 2.73 USD
50-Day Moving Average 3.23 USD
200-Day Moving Average 4.15 USD

IMAB Share Statistics

Avg. Volume (3 month) 347.32K USD
Avg. Daily Volume (10-Days) 228.55K USD
Shares Outstanding 83.1M
Float 38.28M
Short Ratio 5.78
% Held by Insiders 0.75%
% Held by Institutions 64.05%
Shares Short 1.55M
Short % of Float N/A
Short % of Shares Outstanding 1.85%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 845.79%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -24.21%
Return on Equity (ttm) -63.73%

Income Statement

Revenue (ttm) -221563008 USD
Revenue Per Share (ttm) -2.685 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -1859417984 USD
Net Income Avi to Common (ttm) -2411822080 USD
Diluted EPS (ttm) -4.4
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 3.45B USD
Total Cash Per Share (mrq) 41.56 USD
Total Debt (mrq) 74.99M USD
Total Debt/Equity (mrq) 2.49 USD
Current Ratio (mrq) 5.497
Book Value Per Share (mrq) 36.249

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of I-Mab

Country United States
State N/A
City Shanghai
Address New Bund Center
ZIP 200124
Phone 86 21 6057 8000
Website https://www.i-mabbiopharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Q&A For I-Mab Stock

What is a current IMAB stock price?

I-Mab IMAB stock price today per share is 1.86 USD.

How to purchase I-Mab stock?

You can buy IMAB shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for I-Mab?

The stock symbol or ticker of I-Mab is IMAB.

Which industry does the I-Mab company belong to?

The I-Mab industry is Biotechnology.

How many shares does I-Mab have in circulation?

The max supply of I-Mab shares is 80.7M.

What is I-Mab Price to Earnings Ratio (PE Ratio)?

I-Mab PE Ratio is now.

What was I-Mab earnings per share over the trailing 12 months (TTM)?

I-Mab EPS is -3.74 USD over the trailing 12 months.

Which sector does the I-Mab company belong to?

The I-Mab sector is Healthcare.

I-Mab IMAB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.79B USD 16347.38 USD 16420.92 USD 4.79B USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Golden Dragon China Inde HXC 6117.19 USD
+0.3
6112.34 USD 6177.64 USD
NASDAQ Global Market Composite NQGM 2283.98 USD
+0.52
2277.12 USD 2296.84 USD
NASDAQ Biotechnology NBI 4429.97 USD
-0.36
4426.59 USD 4461.88 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD